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Abstract
The chemotherapeutic doxorubicin (DOX) induces DNA double-strand break (DSB) damage. In order to identify conserved
genes that mediate DOX resistance, we screened the Saccharomyces cerevisiae diploid deletion collection and identified 376
deletion strains in which exposure to DOX was lethal or severely reduced growth fitness. This diploid screen identified 5-fold
more DOX resistance genes than a comparable screen using the isogenic haploid derivative. Since DSB damage is repaired
primarily by homologous recombination in yeast, and haploid cells lack an available DNA homolog in G1 and early S phase,
this suggests that our diploid screen may have detected the loss of repair functions in G1 or early S phase prior to complete
DNA replication. To test this, we compared the relative DOX sensitivity of 30 diploid deletion mutants identified under our
screening conditions to their isogenic haploid counterpart, most of which (n=26) were not detected in the haploid screen.
For six mutants (bem1D, ctf4D, ctk1D, hfi1D,nup133D, tho2D) DOX-induced lethality was absent or greatly reduced in the
haploid as compared to the isogenic diploid derivative. Moreover, unlike WT, all six diploid mutants displayed severe G1/S
phase cell cycle progression defects when exposed to DOX and some were significantly enhanced (ctk1D and hfi1D)o r
deficient (tho2D) for recombination. Using these and other ‘‘THO2-like’’ hypo-recombinogenic, diploid-specific DOX
sensitive mutants (mft1D, thp1D, thp2D) we utilized known genetic/proteomic interactions to construct an interactive
functional genomic network which predicted additional DOX resistance genes not detected in the primary screen. Most
(76%) of the DOX resistance genes detected in this diploid yeast screen are evolutionarily conserved suggesting the human
orthologs are candidates for mediating DOX resistance by impacting on checkpoint and recombination functions in G1 and/
or early S phases.
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Introduction
Doxorubicin (DOX) is a highly effective anthracycline
chemotherapeutic agent for many solid tumors including those
of the breast however, dosage has to be carefully monitored to
avoid the potentially life threatening complications associated
with cardiotoxicity. Furthermore, in some cases tumors can
acquire resistance to DOX greatly reducing its efficacy. In some
cases these two factors can severely limit the clinical usage of
this class of drugs. The mechanism of cardiotoxicity is unclear
but it has been suggested that multiple processes are involved
[1]. Mitochondrial failure has been suggested as a probable
causative factor because DOX interacts with mitochondrial
enzymes to induce highly reactive oxygen species (ROS) that
immediately target nearby mitochondrial structural components
including DNA to cause single and double strand breaks (SSBs
and DSBs) [2,3]. Moreover, DOX-induced ROS can also
inactivate other biomolecules critical to mitochondrial function
including lipids and proteins. Furthermore, as a chromosomal
DNA damaging agent, DOX has been proposed to induce
chromosomal DSB DNA damage by mechanisms other than
ROS production including: 1) direct inhibition of type II
topoisomerases [4–6]; 2) alkylation or intercalation with DNA
[7]; 3) DNA crosslinking which inhibits unwinding and
replication [8]; 4) or transcription inhibition [7]. Thus, DOX
appears to be able to induce DSB damage by multiple
mechanisms that could occur throughout the cell cycle
including G1 and S phases.
The ability of tumors to simultaneously develop resistance to
many drugs has been termed multidrug resistance (MDR) and
frequently occurs following DOX treatment. Potential mecha-
nisms for this acquired resistance include upregulation of
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downstream effector pathways including p53 [12] or Bcl-2
mediated apoptosis [13]. Altered expression of critical components
within repair related pathways have also been found to confer
resistance to DOX-induced DNA damage including type II
topoisomerases [4,5,14], p53 [12,15], DNA ligase IV and DNA-
PK [16], 14-3-3sigma [17] and Rad51 [18]. Other components in
pathways with no known repair function have also been implicated
including ALDH4 [19], cathepsin D [20], Nrf2 [21]. Which of
these genes or pathways, if any, are the most relevant for specific
types of cancer remains uncertain.
To identify highly conserved targets that mediate resistance to
DOX, many studies have successfully utilized the genetic
accessibility of the model organism Saccharomyces cerevisiae [22–
24,5,25–30,31–38]. These studies have clearly implicated both the
type II topoisomerases and the mitochondria as targets that
mediate hypersensitivity to this cytotoxic drug. One study of
particular interest was a genome-wide screen in the haploid
deletion collection which identified 71 gene deletions that had
enhanced sensitivity to DOX [38].
To further elucidate the mechanism of DNA damage
resistance in S. cerevisiae, we screened the diploid deletion
collection for mutants that are sensitive to doxorubicin. In this
genome-wide screen, we identified 376 deletion mutants that are
sensitive to the lethal and/or growth inhibitory effects of DOX
compared to the wild type parental strain. This mutant
collection is significantly enriched for deletions that show cross
sensitivity to IR and/or G1 cell cycle defects. Our screen in the
diploid organism identified 5-fold more DOX resistance genes
(376 versus 71) than a similar genome-wide screen for
doxorubicin sensitive mutants performed in the isogenic haploid
strain [38]. Unlike haploids, diploids have the unique capability
for recombinational repair of DSB damage prior to the
completion of DNA replication and suggests we have identified
genes that specifically affect repair of DOX-induced damage in
G1 or early S phases.
To test this, we directly compared the relative sensitivity of
diploid versus haploid deletion for genes that were identified in
the diploid screen but not in the haploid screen. Concurrently,
we screened for cross sensitivity to the S phase specific DNA
damaging agents HU and MMS. All diploid strains examined
demonstrated sensitivity to DOX and the S phase specific
inhibitors HU or MMS. Of 30 mutants tested, 24 demonstrated
enhanced sensitivity to doxorubicin as both a diploid and an
isogenic haploid when compared to the repair competent WT
strains. Thus the higher DOX doses used in the diploid screen
was more effective in identifying DOX resistance genes.
However, deletions of BEM1, CTF4, CTK1, HFI1, NUP133
and THO2 showed greatly enhanced sensitivity to DOX as a
diploid when compared to the isogenic haploid stains. Subse-
quent characterization revealed that these gene deletions appear
to affect G1 repair processes with (CTF4, NUP133, CTK1 and
HFI1) or without (THO2 or BEM1) instability of the MAT locus.
Thus the use of the diploid deletion collection has facilitated the
detection of an extensive network of G1/S phase specific repair
genes that confer overlapping resistance to DOX as well as IR
and other agents. Many of these are highly conserved (76%) and
form a large interactive network that associates with genes that
impact on numerous cellular processes including mitochondrial
function. Genetic defects and/or polymorphisms in these
conserved DOX resistance genes may mediate cardiotoxicity in
patients undergoing DOX chemotherapy or serve as biomarkers
for therapeutic response to DOX chemotherapy in human
tumors.
Materials and Methods
Yeast strains
Deletions of individual non-essential radiation resistance genes
(or ORFs) were made in MATa (BY4741) and MATa (BY4742)
haploid S. cerevisiae strains as part of The Saccharomyces Gene
Deletion Project and subsequently mated to produce the isogenic
diploid deletion strains. The diploid deletion strains were
purchased in 96 well microtiter dishes from Open Biosystems
and stored at 270uC. Isogenic MATa haploid deletion strains were
obtained from the Yeast Model Systems Genomics Group at Duke
University. MATa haploid deletion strains used in this study were
purchased from Open Biosystems.
Doxorubicin and zymocin chemical genomic screening
A doxorubicin (DOX) stock solution (10 mg/ml in sterile H20)
was used to prepare DOX YPD agar plates at two concentrations
(25 or 50 mg/ml). DOX was added to cooled YPD agar at the time
of pouring and plates were allowed to solidify at room temperature
and used immediately for screening the diploid deletion collection.
Strains from the frozen deletion collection individually arrayed in
96 well dishes were thawed and aliquots (,2 ml) were transferred
using a multi (48) pin ‘‘pronging’’ device to YPD and YPD DOX.
Concomitant with the DOX screen, zymocin screening of the
deletion collection was also performed by replica pronging directly
from the thawed 96 well dishes onto YPD plates containing 0,
33% or 66% crude zymocin. Zymocin containing YPD plates
were made as previously described [39] (see below for brief
description). DOX sensitive strains were identified after 2 days
incubation at 30uC. Zymocin resistant deletions were identified
following 1–2 days of incubation at 30uC. Zymocin sensitive
strains were identified following 3 days incubation at 30uC.
Selected strains identified as DOX or zymocin sensitive or
zymocin resistant in the primary screen were subsequently
confirmed by growing individual isolates (and WT) in 200 mlo f
YPD in 96 well dishes for two days. These cells were serially
diluted (5-fold) in liquid YPD and ,2 ml of each dilution was
replica plated by pronging to either YPD, YPD containing DOX
or YPD containing zymocin. Resistance to zymocin was scored
following 2 days incubation. Zymocin sensitivity was scored
following 3 days incubation at 30uC.
Strains were screened for hydroxyurea (HU) and methyl
methane sulfonate (MMS) sensitivity using a similar dilution
plating procedure as previously described [40]. Briefly at least two
individual isolates of each strain were grown in liquid YPD
(200 ml) for two days at 30uC in 96 well microtiter dishes. Serial 5
fold dilutions of these stationary cell cultures were made in fresh
YPD and ,2 ml of each dilution was transferred to a control YPD
plate and a YPD plate containing the chemical DNA damaging
agent using the replica plating device described above. Inhibition
of cell growth was determined after 24 and 48 h growth at 30uC.
Zymocin preparation
Deletion strains were exposed to zymocin on plates either
directly from the diploid deletion collection arrayed in 96 well
dishes or using the dilution pronging technique described above.
Alternatively, selected deletion strains and WT were grown for two
days in liquid YPD (filter sterilized) in 96 well plates and serial 5
fold dilutions were made in water. Cells (,2 ml of each dilution)
were replica transferred to YPD and YPD+zymocin plates. YPD
plates containing zymocin were made by growing K. lactis strain
AWJ137 on filter sterilized liquid YPD for two days at room
temperature. Briefly, two parts of a sterile YPD filtrate of
conditioned medium from the 48 hr culture of the K. lactis strain
Doxorubicin Repair in G1
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plates. The 33% zymocin plates were made in a similar manner
with the exception that 1 part conditioned medium was mixed
with 2 parts liquid YPD agar which had been cooled following
sterilization by autoclave. The final agar concentration was 2%.
Plates were immediately poured and allowed to solidify at RT.
Cell cycle progression analysis
WT and selected DOX sensitive deletion strains were examined
for cell cycle progression following exposure to DOX as previously
described [40,41,39]. Briefly, single unbudded (G1) cells from
logarithmically growing cultures in YPD liquid cultures were
arrayed into a 465 (20) cell grid pattern onto YPD and YPD plates
containing DOX (50 mg/ml) using a Singer MSM dissecting
microscope. Each grid was positioned such that all cells were
visible within one field of view at 3006magnification. Cell cycle
progression was determined by microscopic observations at hourly
intervals and photographed using an Olympus Q-color 3 camera.
Recombination assay
The PCR mediated gene conversion assay utilizing the his3D1
allele as a target for recombination has been previously described
[40]. Briefly, 1 mg of a PCR fragment that spans the internal
deletion within the his3D1 allele was transformed into WT and
various diploid deletion strains [42] and the frequency of gene
conversion of the his3D1 allele to HIS3 determined by plating to
synthetic complete (SC) medium lacking histidine. To control for
relative transformation efficiency, 200 ng of the plasmid pRS315
containing the LEU2 selectable marker was co-transformed along
with the PCR product containing the HIS3 fragment before
plating an aliquot of the transformation mix to SC medium lacking
leucine. Relative gene conversion frequencies were normalized to
that seen in WT.
Mating-type determinations
WT and various diploid deletion strains were patched from
single colony isolates or single colonies themselves grown on YPD
plates were mated on fresh YPD plates to mating type tester strains
147 (MATa pet8 met2 arg1 his7 met14 [KIL-k]) and 148 (MATa pet8
met2 arg1 his7 [KIL-k] disomic for XI: met14/MET14) for 24 hours at
30uC. Mated isolates were subsequently replica plated to minimal
and YPD media and allowed to grow for 24–48 hours at 30uC.
Results
Checkpoint, recombinational repair and mitochondrial
functions are required for doxorubicin resistance in
diploid yeast strains
We have described a large interactive network of ionizing
radiation resistance genes in which the CCR4-NOT complex
plays a key role [39]. Deletions within the CCR4 damage response
network are sensitive to IR-induced DSB damage as diploids but
not as haploids and appear to function as checkpoint adaptation
genes. Moreover, lethality induced by doxorubicin (DOX) is
mediated indirectly by reactive oxygen species (ROS) generated
within the mitochondrion or through inhibition of topoisomerase
II both of which induce DSB damage. Thus, similar to IR, DOX-
induced DSB damage requires the recombinational repair activity
of the RAD52 group of recombinational repair genes. In order to
establish an appropriate screening concentration for exposure of
the diploid deletion strain collection to DOX, we examined
selected IR sensitive mutant strains within the CCR4-NOT
complex (ccr4D, dhh1D, pop2D and dbf2D) which have moderate IR
sensitivity and recombination repair deficient strains that are
extremely IR sensitive (genes within the RAD52 epistasis group) to
increasing concentrations of DOX using a multi-pin replica
plating device (10, 25 and 50 mg/ml; Fig. 1A). A dose dependent
decrease in survival was observed for all of the mutant strains with
the recombination deficient strains demonstrating the greatest
sensitivity to DOX. For mutant strains that have moderate
sensitivity to agents that induce DSB damage (such as those within
the CCR4 damage response pathway), a dose of 50 mg/ml was
required to see a decrease in survival for undiluted cells, (i.e.,
similar to the conditions expected for screening the deletion
collection directly from the arrayed 96 well plate format). For
strains hypersensitive to DOX (such as those mutants within the
RAD52 group of repair genes), a dose of 25 mg/ml was adequate
for observing decreased survival of undiluted cells. However, at a
dose of 10 mg/ml the undiluted DSB sensitive deletion strains did
not show a significant decrease in survival when compared to WT.
Therefore, in order to identify gene deletions that confer both
moderate and severe hypersensitivity to the lethal effects of DOX,
we screened the arrayed diploid deletion collection at both 50 and
25 mg/ml of DOX in YPD medium.
Deletion of genes within the CCR4 damage response network
results in cell cycle checkpoint adaptation defects during the G1 to
S phase transition following DSBs or replication stress [39]. In
order to initially characterize the cell cycle response to DOX, we
examined cell cycle progression of unbudded (G1) checkpoint
deficient diploid ccr4D to DOX at 25 mg/ml (Fig. 1B) and 50 mg/
ml (Fig. 1C). These were compared to the repair proficient WT
and recombination deficient rad51D diploid cells exposed to DOX
at the same doses. Mutant ccr4D cells clearly demonstrated a severe
cell cycle progression defect when compared to WT at both doses
(Fig. 1B, C). Strikingly when exposed in G1 to either low (25 mg/
ml) or high concentration of DOX (50 mg/ml), many ccr4D cells
(40 and 70% respectively) failed to progress into S phase and
arrested permanently as single cells in G1. Following prolonged
exposure to DOX, most of these diploid ccr4D cells underwent lysis
in a manner similar to that seen following exposure to
hydroxyurea [39]. This DOX-induced cellular lysis was observed
in both G1 arrested cells and those that did progress into S phase
(Fig. 1B, C). A fraction of ccr4D cells (20%) failed to arrest at either
G1 or in S phase and formed microcolonies of 3 or more cells
following DOX exposure at the low dose (Fig. 1B). Similar to that
seen following IR exposure, recombination deficient rad51D cells
transited from G1 to S phase and arrested as large budded cells
following exposure to low doses of DOX (Fig. 1B). The majority of
these recombination deficient cells (80%) adapted to the DOX-
induced cell cycle arrest and resumed cycling to form microcol-
onies of 3 or more cells. At the higher DOX dose the
recombination deficient rad51D cells failed to progress and arrested
permanently in G1 (Fig. 1C). WT diploid cells progressed rapidly
into microcolonies following exposure to high doses of DOX
(Fig. 1C). In the absence of DOX, all strains showed high viability
and rapid cell cycle progression when plated to YPD as single G1
cells (Fig. 1D). Thus the checkpoint functions associated with
CCR4-mediated damage responses are required for resistance to
DOX which, in the absence of Ccr4 induced a prolonged G1
arrest followed by cellular lysis. A few ccr4D cells escaped G1 arrest
and proceeded into S phase where a permanent cell cycle arrest
and lysis was observed. A dose dependent arrest phenotype was
observed for the rad51D strain in which a permanent G1 arrest
occurred at the high DOX dose. At low DOX doses, rad51D cells
were capable of adapting to the DOX-induced damage and
resumed cell cycling to form microcolonies. The hypersensitivity of
diploid deletion mutants within members of the RAD52 epistasis
Doxorubicin Repair in G1
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strains.(A)Isogenic ionizingradiation(IR)sensitivediploiddeletionstrainsweregrownat30uCfortwodaysinliquidYPDmediumin96wellplates.Serial
5-folddilutionsweremadeinsterilewaterand2 mlaliquotswerereplicaplatedtoYPDsolidmediumwithandwithouttheindicateddosesofdoxorubicin.
Plates were subsequently incubated for 3 days at 30uC. Arrows indicate the direction of decreasing cell concentration. When compared to WT (row 1),
defects in genes within the CCR4-NOT complex (rows 2–5) confer checkpoint adaptation functions and show intermediate sensitivity to doxorubicin.
Defects in members of the RAD52 recombination repair group (rows 6–8) are required for double strand break repair and are hypersensitive to
doxorubicin. (B) Diploid WT, ccr4D and rad51D cells were grown to logarithmic phase in liquid YPD and individual unbudded (G1) cells were plated in a
564 cell grid pattern to YPD containing doxorubicin at the indicated dose within one microscopic field of view using a Singer MSM micromanipulator.
DOX-induced inhibition ofcellcycle progression in G1andG1/Sphases ofthecell cyclewas monitored byphotomicroscopyathourlyintervals.Cells were
incubated at 30uC during cell cycle progression analysis. (C) Similar topanel B exceptindividual unbudded cells were gridded onto YPDplates containing
50 mg/ml DOX. (D) Similar to panel B except individual unbudded cells were gridded onto YPD medium without doxorubicin to demonstrate normal cell
cycle progressionand100%cellviability. (E) Isogenic respiratory competentandpetiteWT, ccr4D and pop2D strainswere grown in liquid YPDand serially
dilutedin96wellplates as describedinpanelA.Boththeccr4D and pop2Dpetitestrainsshowenhancedresistancetothelethaleffectsofdoxorubicin.(F)
Similar to panel C except individual unbudded cells were from petite strains that lacked respiratory function.
doi:10.1371/journal.pone.0005830.g001
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major contributor to lethality that require repair by mechanisms of
homologous recombination.
Doxorubicin-induced ROS mediates lethality in G1
Interaction of DOX within mitochondria has been proposed to
result in the generation of reactive oxygen species (ROS) that
contributes to cellular lethality. To examine whether mitochon-
drial processing of DOX contributes significantly to lethality and/
or checkpoint arrest in diploid yeast we ‘‘cured’’ the WT, ccr4D
and pop2D diploid strains of functional mitochondria by generating
petite mutants that fail to grow using glycerol as a carbon source.
The relative survival following DOX exposure of the isogenic WT,
ccr4D and pop2D strains with and without mitochondrial function
was determined (Fig. 1E). Although the loss of mitochondrial
functions enhanced DOX resistance in both the ccr4D and pop2D
mutants it did not totally eliminate DOX-induced lethality
suggesting that survival following DOX exposure is only in part
dependent on the maintenance of functional mitochondria.
Moreover, this suggests that multiple mechanisms are responsible
for DOX-induced lethality in diploid yeast.
In order to determine if the loss of mitochondrial functions
affected cell cycle responses to DOX we examined cell cycle
progression of logarithmic diploid WT, ccr4D (Fig. 1F) and pop2D
(data not shown) G1 cells without functional mitochondria (i.e.,
petites) following exposure to DOX. In the absence of functional
mitochondria, most ccr4D and pop2D cells rapidly progressed from
unbudded (G1) cells into budded (S phase) cells (Fig. 1F). In petite
diploid ccr4D cells that were respiratory deficient, only 15% (3/20)
of G1 cells exposed to DOX remained permanently arrested in G1
as opposed to those in isogenic respiratory proficient ccr4D cells in
which 75% (15/20) remained permanently arrested in G1
(Fig. 1C). Similarly, a prolonged DOX-induced G1 arrest was
more evident in diploid pop2D strains that were respiratory
proficient (50% arrested in G1) as compared to those that were
respiratory deficient (20% arrest in G1; data not shown). Thus the
prolonged DOX-induced G1 arrest observed in strains defective in
components of the CCR4 damage response required the presence
of functional mitochondria and implicates ROS as a DNA damage
intermediate that elicits damage in G1.
A genome-wide diploid screen identifies 376 gene
deletions that are sensitive to doxorubicin
The diploid deletion collection has been useful for identifying
ionizing radiation (IR) repair associated genes that function
specifically in G1 [39]. To identify new DOX resistance genes,
we utilized a ‘‘spot’’ testing procedure identical to that which we
had previously used to identify IR resistance genes. In order to see
significant lethality for undiluted cells, the diploid deletion
collection was simultaneously screened at two concentrations
(Fig. 1A; 25 and 50 mg/ml). Deletion strains arrayed in the 96 well
format were replica pronged to YPD plates containing the two
concentrations of DOX and growth inhibition scored by
comparison to growth on YPD plates without DOX. Strains that
exhibited the most hypersensitivity to DOX showed complete
inhibition and no residual growth on both the 25 and 50 mg/ml
DOX were scored as a ‘‘3’’. Deletions that showed moderate
DOX hypersensitivity demonstrated complete inhibition at 50 mg/
ml DOX but only partial growth inhibition on 25 mg/ml and were
scored as a ‘‘2’’. Strains that were slightly hypersensitive to DOX
were those showing complete growth inhibition on 50 mg/ml
plates but little or no growth inhibition on 25 mg/ml DOX. These
were scored as a ‘‘1’’ (Supplementary Table S1). In addition to this
scoring scheme other deletion strains lacked complete killing, but
instead showed a slowed growth response to DOX on YPD plates
when compared to that observed for the majority of deletion
strains that were resistant to DOX and displayed rapid growth
during initial DOX screening on YPD (Supplementary Table S2).
A total of 376 diploid deletion strains demonstrated either
hypersensitivity (n=209) or reduced growth rate (n=167) when
exposed to DOX. This represents ,8% of the non-essential genes
represented within the diploid deletion collection. Remarkably,
this collection of DOX sensitive gene deletions is significantly
larger (.5 fold) than that found in a similar screen using the
isogenic haploid deletion collection from which only 71 deletion
strains were identified (Table 1; Supplementary Tables S1 and S2).
Of the 71 mutants identified in the haploid screen, we identified 43
(61%) deletions as being sensitive to DOX in our diploid screen.
Of the remaining 28 haploid mutants not found in the diploid
screen, we re-examined 10 of the most DOX sensitive haploid
deletions detected (those described as being SSS or SS [38]). Using
dilution plating to 50 and 25 mg/ml DOX, we found that diploid
vma21D, hom6D, trp1D and mac1D (i.e. 40% of strains tested) were
sensitive to DOX as a diploid (data not shown) and therefore
missed using our screening protocol in the diploid deletion
collection. The other six diploid deletion strains (afg3D, erg3D,
mrpl6D, mrpl37D, vps36D and yor199wD) were resistant to DOX as
a diploid suggesting these may represent a subset of haploid-
specific DOX-resistance genes. These six gene deletion strains
were not examined further.
Doxorubicin sensitive mutants are enriched for genes
required for G1-dependent functions
DOX is a well-characterized chemotherapeutic that induces
DNA damage by multiple mechanisms including the production of
ROS by interaction with the mitochondria, direct inhibition of
topoisomerase II or direct DNA interactions (by intercalation,
alkylation and/or crosslinking). All of these processes are known to
induce DSB damage. Therefore, it is not surprising that a subset of
DOX sensitive genes significantly overlap with those that show
sensitivity to IR and oxidative damage induced by H2O2 and other
chemicals that act in G1 (Table 1; Supplementary Tables S1 and
S2). Of the 376 DOX sensitive diploid mutants identified, 24.5%
(92 deletions) had been previously found in our genome-wide
screen for IR resistance genes in the diploid background including
those required for the recombinational repair of IR-induced DSBs
(RAD50, RAD51, RAD52, RAD54, RAD55, RAD57 and RAD59).
This overlap is 6 fold more than would be expected by chance
alone. Furthermore, 33% of the DOX sensitive mutants (124
deletion mutants) overlap with those that confer resistance to
oxidative stress damage including sod1D. This is .3 fold more
than would be expected by chance alone and confirms that a
significant amount of the lethality induced by DOX in yeast can
be attributed to lesions indirectly induced by ROS. Moreover,
highly conserved mitochondrial associated gene deletions were
also overrepresented among the DOX-sensitive mutants (Supple-
mentary Tables S1 and S2) suggesting that defects in mitochondria
associated functions contribute to DOX induced ROS mediated
lethality.
Among the diploid DOX resistance mutants, many (24.3%)
overlap with those that were found to affect cell size control
(Table 1; Supplementary Tables S1 and S2), a function that is
regulated in the G1 phase of the cell cycle at START [43,44]. This
enrichment was .2.6 fold greater than that expected by chance
alone and suggests that many DOX genes may function within G1
to confer DNA damage resistance. Finally, the subset of DOX
sensitive deletion mutants were greatly enriched for mutants that
showed G1 cell cycle defects either spontaneously or following
Doxorubicin Repair in G1
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(LoaOOH) that arrests cells in G1 [45]. In fact 55% (26/47) of
the deletion mutants that failed to arrest in G1 following LoaOOH
exposure were sensitive to DOX suggesting that defects in G1
associated checkpoint control may represent a significant propor-
tion of the DOX resistance genes identified in the diploid yeast
screen. This also indicates that a substantial number of lethal
DOX-induced lesions are inflicted during the G1 phase in diploid
yeast.
Zymocin is a toxin secreted by the yeast K. lactis and has been
shown to induce a prolonged lethal G1 arrest in S. cerevisiae [46,47].
We previously determined that diploid IR sensitive deletions were
enriched for those that were also sensitive to the toxin zymocin
[39] and defects in the G1 associated DNA damage checkpoint
mutant HRR25 confer zymocin resistance [47]. We therefore
concomitantly screened for sensitivity to zymocin during the
screen for DOX. In order to initially determine the relative
sensitivity of diploid deletion mutants to the toxic action of
Table 1. A genome-wide screen in the yeast diploid deletion collection identifies 209 doxorubicin resistance genes enriched for
those that show cross sensitivity to zymocin, ionizing radiation, loss of G1 size control and oxidative damage.
Zymo
1 IR
2 G1 size
3 Oxid
4 Yeast DOX resistance gene Conserved human ortholog
S S S S ASF1, CCR4, DBF2, HFI1, MMS22, POP2, RAD50,
RTT109, YDJ1
ASF1A, CNOT6, STK38L, none, ANKRD12, CNOT8, RAD50,
RTT109, HSP40
R ADK1, AKR1, ARP5, BEM1, MDM20, RPB9 AK2, ZDHHC17, ACTR5, SH3PXD2B, C12orf30, POLR2I
R S TOP3, TPS1, YAF9, YEL033W TOP3A, none, YEATS4, none
R CLC1, CTF4, DHH1, DOC1, GRR1, GUP1, NOT5,
OCH1, RAD51, RAD52, RAD54, TSR2, TUP1, VMA7,
XRS2, YLR235C
CLTA, WDHD1, DDX6, ANAPC10, FBXL20, HHATL, CNOT3, none,
RAD51, RAD52, RAD54L, TSR2, WDR5, ATP6V1F, NBS1, none
R S S GAL11, IFM1, IMP2’, MSE1, MSM1, PEP3, PHO85,
RNR4, ROX3, RTS1, SNF5, SUV3, SWI6
MLL2, MTIF2, SFRS12, EARS2, MARS2, VPS18, CDK2, RRM2, none,
PPP2R5D, MLL2, SUPV3L1, AKAP9
R ADH1, ANP1, BEM4, BUD25, IES6, MIP1, MNN9,
MNN10, MSD1, PIN4, RNR1, SHP1, SPT7, TCO89,
VPS34
ADH1B, TNRC6A, none, none, C18orf37, POLG, none, none,
DARS2, MLL5, RRM1, NSFL1C, BAZ1A, DSPP, PIK3C3
R S BUD23, ERG4, LST4, PFK26, PGD1, PHO2, PKR1,
PTC1, REG1, SNF2, SNF6, SOD1, SWI3, TAT1, VAN1,
VMA2, VMA4, YJL175W
WBSCR22, LBR, LOC100133790, PFKFB3, MUC7, PITX1, none,
PPM1B, DSPP, SMARCA2, none, SOD1, SMARCC2, SLC7A14,
none, ATP6V1B2, ATP6V1E1, none
R ACO1, BUD16, CCW12, CUP5, DOA4, ERG6, GAS1,
HEX3, HOM2, HOM3, HTZ1, KHA1, MSY1, PER1,
RRN10, SAC7, SER2, SLM4, NAB6, VPS64, VMA5,
YOL050C, YOR331C, YPL205C
ACO2, PDXK, LOC100132635, ATP6VOC, USP8, TGS1, MUC21,
HRNR, none, none, H2AFV, TMCO3, YARS2, PERLD1, none,
ARHGAP6, PSPH, none, none, SLMAP, ATP6V1C1, none, none,
none
R S S S PAT1, SLX8, YJL188C PATL1, RNF10, none,
R BCK1, FUN12, HPR1, LGE1, NPL3, PLC1, THO2 MAP3K3, EIF5B, THOC2, FLG, HNRNPR, PLCD4, THOC2
R S RSA1 AKAP9
R ADE12, GON7, LSM7, MMS4, NUP133, RAD55,
RAD57, RAD59, VPH2, YDL041W, YDR433W,
YKL118W, YML009C-A
ADSSL1, none, LSM7, none, none, RAD51L3, RAD51L1, RAD52,
none, none, none, none, none
R S S DBP7, ECM33, MSN5, RPL35A, RPL43A, SAC1,
SAC3, SIN3, SSZ1, UAF30
DDX31, MUC21, XPO5, RPL35, RPL37A, SAC1L, MCM3AP, SIN3A,
HSPA8, SMARCD1,
R ASC1, BUD22, CTK3, FYV5, HIT1, KRE6, MET7,
OPI11, PRO1, RPL39, RPS10A,
GNB2L1, LOC100133599, none, none, none, DSPP, FPGS, none,
ALDH18A1, LOC100133222, RPS10,
R S CBC2, GCR2, HAL5, KCS1, LSM1, NSR1, PDR1,
RPL27A, RPS4A, RPS11B, SAT4, SIN4, VMA13, YAR1
NCBP2, MUC21, PRKAA1, IHPK3, LSM1, NCL, none, RPL27,
RPS4X, RPS11, CHEK1, none, ATP6V1H, FEM1C
R AKL1, CKB1, CKB2, CTI6, YPL182C, CTK1, EDC3,
EGD1, ERV41, GET1, HEM14, HHF1, MDM35, MMS1,
MTQ2, NEW1, NFI1, PSK2, PUS1, PUS7, RDS2, RIS1,
RPA49, RPL12A, RPL13B, RPL20B, RPP1A, RTG1,
SER1, SPT20, TAF14, TCM62, TFP3, THP1, TRK1,
VMA6, YCL007C, YDR049W, YGR160W, YNL140C,
YOL046C, YOR152C, YPL260W, YPL261C
AAK1, CSNK2B, CSNK2B, CYLC1, POU2F1, CRKRS, ATP6V1D,
BTF3L4, ERGIC2, none, PPOX, HIST1H4A, TRIAP1, none,
N6AMT1, GCN20, PIAS4, PASK, PUS1, PUS7, FAM135A, HLTF,
POLR1E, RPL12, RPL13, RPL18A, RPLP1, none, PSAT1, none,
MLLT3, HSPD1, ATP6VOD1, PCID2, DSPP, ATP6VOD1, none,
ANKZF1, LOC645490, none, none, ANKRD26, none, none
1Resistance to the G1 specific toxin zymocin was determined in a screen that was performed in parallel to that for the identification of DOX resistance mutants. A total
of 806 diploid deletion strains (16.6% of nonessential genes) were found to be hypersensitive to zymocin. A total of 106 DOX
S deletion mutants (50.7%) were found to
be cross sensitive to the lethal effects of zymocin. This is 3 fold greater than that expected by chance alone.
2A total of 204 ionizing radiation resistance genes (4% of nonessential genes) were identified in the diploid deletion collection as previously described [40,39]. A total of
59 DOX
S deletions (28.6%) were found to overlap with those that were identified as IR resistance genes. This is 7 fold greater than that expected by chance alonea n d
suggests that DSBs are a significant component of the spectrum of lesions induced by DOX in S. cerevisiae.
3Approximately 500 gene deletions (,10% of nonessential genes) in the haploid deletion collection were found to significantly affect cell size control that is determined
in G1 and regulated by the checkpoint at ‘‘START’’ [43,44]. A total of 74 DOX sensitive mutants (35.4%) were found to overlap with those that affect cell size control.
This is 3.5 fold greater than that predicted by chance alone.
4A total of 456 deletion mutants in the haploid deletion collection (9.4% of nonessential genes) were identified that demonstrated enhanced sensitivity to oxidative
DNA damaging agents [60]. A total of 71 DOX
S mutants (31%) were found to overlap with those determined to be sensitive to oxidative damage. This is 3.3 fold greater
than that predicted by chance alone and suggests that oxidative damage lesions are a significant component of the spectrum of lesions.
doi:10.1371/journal.pone.0005830.t001
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directly from the deletion collection to two different concentrations
of zymocin as previously described [39]. Strains that exhibited the
greatest hypersensitivity to zymocin-induced growth inhibition
upon initial plating showed complete inhibition on both 33% and
66% zymocin and were scored as a ‘‘3’’. Deletions that showed
moderate zymocin sensitivity demonstrated complete inhibition on
66% zymocin but only partial or no growth inhibition on 33%
plates and were scored as a ‘‘2’’. Strains with slight zymocin
sensitivity were classified as those showing partial growth
inhibition on 66% plates with little or no inhibition on the 33%
plates. These were scored as a ‘‘1’’. We identified a total of 806
gene deletions that demonstrated enhanced sensitivity to zymocin
(Westmoreland et al., manuscript in preparation). Of these, 202
(25%) were scored as hypersensitive, 396 (49%) were moderately
sensitive and 208 (26%) were slightly sensitive to zymocin.
Among the zymocin sensitive diploid deletion strains identified
in the primary screen, 103 were found to overlap with our
previously described set of IR sensitive diploid deletion strains
[40,39]. A further 12 ionizing radiation sensitive deletion strains
were found to confer zymocin resistance. Therefore, from the
primary zymocin screening 58% (115/200) of the previously
identified IR resistance genes were found to confer altered
sensitivity to zymocin when deleted. Moreover, 45% of the
DOX sensitive deletion strains (169/376) were found to be
sensitive to zymocin-induced lethality (Table 1; Supplementary
Tables S1 and S2). This suggests that the genetic pathways
responsible for zymocin, IR and doxorubicin resistance signifi-
cantly overlap. Furthermore, since the primary lesion responsible
for DOX and IR-induced lethality is unrepaired DSB damage, this
implies that zymocin-induced cytotoxicity may also result from the
induction of persistent unrepaired DSB. Since zymocin is known
to function in G1, the overlap between the zymocin responsive
gene network and those genes that mediate IR and DOX
resistance suggests that a significant fraction of DOX resistance
similarly occurs in G1.
Identification of diploid-specific doxorubicin resistance
genes
The overlapping sensitivity of our diploid DOX sensitive
deletion strains to the G1 specific toxin zymocin as well as with
mutants sensitive to oxidative damage and those that regulate cell
size control in G1 suggests that a significant fraction of the lethal
activity of DOX occurs in the G1 phase of the cell cycle.
Furthermore, as compared to haploids, diploid yeast are capable
of repairing DSB via recombination in G1 due to the availability
of a chromosome homolog. This suggests that among the mutants
identified exclusively in the diploid screen and absent in the
haploid screen, some may exert repair activity specifically in G1.
Alternatively, since we utilized a dose higher than that used in the
haploid screen (50 and 25 mg/ml as compared to ,11 mg/ml), this
may have allowed the identification of more DOX resistance
genes. To test this directly, we compared (relative to WT) the
haploid and diploid DOX sensitivities for 26 mutants detected in
the diploid DOX screen but not found in the haploid DOX screen
as well as 4 diploid sensitive mutants (adk1D, bem1D, hfi1D and
rtt109D) that were also detected in the haploid DOX screen
(Fig. 2A; Table 2). In addition, we selected these mutants based on
their known cross sensitivity to IR as diploids [40,39]. Among
these we found that akr1D, arp5D, ccr4D, dbf2D, dhh1D, hpr1D,
lge1D, lsm7D, mdm20D, mms4D, mms22D, nup133D, och1D, pat1D,
plc1D, pop2D, rad54D, rad59D, rpb9D, slx8D, tho2D, tup1D, vma7D
and yaf9D (Fig. 2A, Table 2) all showed sensitivity to DOX in the
isogenic haploid strain backgrounds when compared to WT. With
the exception of ctf4D, ctk1D and hfi1D, all of these haploid MATa
mutants showed cross sensitivity to the S phase specific DNA
damaging agents HU or MMS indicating that these deletions have
repair associated defects that extend into S phase. Interestingly,
some deletions (mms4D, tup1D and yaf9D) were sensitive to MMS
but completely insensitive to HU as both haploid and diploid
genotypes (Table 2).
For six of the deletion strains examined (bem1D, ctf4D, ctk1D,
hfi1D, nup133D and tho2D), the diploid deletions showed
hypersensitivity to DOX when compared to WT ($125-fold)
whereas the isogenic haploid derivatives showed little (bem1D,
hfi1D, nup133D and tho2D) or no (ctf4D and ctk1D) sensitivity
compared to WT (Fig. 2A; Table 2). For three of these mutants
that showed diploid-specific sensitivity to DOX (ctf4D, ctk1D and
hfi1D), a similar diploid-specific hypersensitivity to cell killing was
observed in response to the S phase specific DNA damaging agents
HU and MMS. For the remaining three deletions that showed
diploid-specific hypersensitivity (bem1D, nup133D and tho2D),n o
diploid-specific hypersensitivity to HU or MMS was observed.
Instead, both the haploid and diploid mutant derivatives had
similar sensitivity to HU and MMS when compared to their WT
counterparts. Interestingly, one diploid deletion (slx8D) showed
enhanced sensitivity (25-fold) to the lethal effects of MMS when
compared to the WT whereas the haploid deletion did not and
both the diploid and haploid deletions showed similar hypersen-
sitivity to DOX (.125 fold) and HU (125-fold; Table 2). Since, the
haploid MATa variant of the hfi1D strain was described as
hypersensitive to DOX, and both the ctk1D and hfi1D diploids
display enhanced levels of mating with MATa tester strains (see
below), we compared the relative sensitivity of the MATa haploid
derivatives to DNA damage when compared to the WT
counterpart. In contrast to the hypersensitivity of the diploid
deletions to DOX, both the MATa and MATa haploid variants of
the hfi1D and ctk1D strains demonstrated little or no sensitivity to
DOX (Fig. 2B) suggesting that under our experimental conditions
resistance to DOX mediated by CTK1 and HFI1 is primarily a
diploid specific event in the BY4743 strain background. Moreover,
we remade the ctk1D deletion in the MATa haploid BY4742 strain
background and confirmed that it was not sensitive to DOX (data
not shown) suggesting that the haploid ctk1D strains (Fig. 2B) had
not acquired genetic suppressors of DOX-induced toxicity.
Both HPR1 and THO2 have been identified as genes which
encode components of the THO complex that are required for
transcription elongation and participate in mitotic recombination
processes [48,49]. Surprisingly, the hpr1D and tho2D mutants
displayed different phenotypes with respect to the diploid-specific
hypersensitivity to DOX. While the diploid tho2D mutant was
hypersensitive (.125-fold greater than WT) to DOX, the isogenic
haploid tho2D mutant displayed only a modest (5-fold greater than
WT) DOX sensitivity. However, both the haploid and diploid
hpr1D mutants were hypersensitive (.125-fold greater than WT)
to DOX (Table 2). We therefore examined the relative DOX
sensitivity of isogenic haploid and diploid derivatives of various
deletion mutants (mft1D, thp1D and thp2D) that encode other
putative components of the THO complex that participate in
mitotic recombination [49,50]. Of these three additional THO
associated mutants, only thp1D was detected in the initial diploid
DOX screen (Table 1, Supplemental Table S1). Similar to the
tho2D mutant, all three diploid deletion strains (mft1D, thp1D and
thp2D) demonstrated enhanced hypersensitivity to DOX when
compared to that in the isogenic haploid derivative (Table 2).
Similar levels of sensitivity to HU and MMS were observed for the
haploid and diploid derivatives of mft1D and thp1D when
compared to WT. Although the haploid and diploid derivatives
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fold greater than WT), the diploid derivative of the thp2D mutant
showed enhanced hypersensitivity to MMS (25-fold greater than
WT) compared to the haploid derivative which was not MMS
sensitive (Table 2). Thus, for the majority of THO complex
mutants, the diploid deletions demonstrate enhanced DOX
sensitivity when compared to the isogenic haploid derivatives.
Since mating type transcription regulation alters relative
expression levels and useage of DSB repair pathways (homologous
recombination versus NHEJ), we examined whether the a1 a2
transcriptional regulators (from MAT) constitutively expressed
from a selectable plasmid (pCB115) could reinstate sensitivity to
DOX in the haploid deletion strains that showed sensitivity only
when the deletion was established in the isogenic diploid strain.
This plasmid has been previously characterized and confers a
nonmating (diploid) phenotype in haploid BY4741 and BY4742
cells [41]. When the plasmid pCB115 was established in haploid
MATa and/or MATa bem1D, ctf4D, ctk1D, hfi1D, nup133D or
tho2D derivatives and these were exposed to DOX (25 or 50 ug/
ml) in YPD agar, no increased sensitivity was detected when
compared to the same strains containing the empty plasmid
pRS315 (data not shown). This suggests that it is the diploid state
and the availability of an additional recombinogenic chromosome
(2n) rather than the diploid MAT expression pattern which is
required to confer sensitivity to DOX in the diploid deletion
strains.
Diploid-specific doxorubicin sensitive mutants have
altered mating type expression
It has been established that in diploid cells which exhibit altered
MAT expression patterns, sensitivity to DSB damage is increased
due to a decrease in recombination capability [51–53]. Moreover,
many diploid deletion strains that exhibited IR hypersensitivity as
a diploid showed less sensitivity to IR as haploids [40]. The
enhanced sensitivity of some diploid deletion strains to DOX when
compared to the isogenic haploid strain may indicate that
alterations in mating type expression patterns in the diploid may
be responsible for the enhanced lethality. To examine this
possibility, we mated the diploid deletion strains that displayed
diploid-specific DOX hypersensitivity (tho2D, bem1D, nup133D,
ctf4D, ctk1D and hfi1D)t oMATa and MATa mating-type tester
strains to determine if mating in these diploid deletion strains was
enhanced when compared to the non-mating WT diploid strain
(Fig. 2B). Following individual mass matings of the diploid deletion
strains with haploid MATa and MATa strains, we observed
aberrant mating with either the MATa tester strain (ctk1D, hfi1D
and nup133D) or both the MATa and MATa tester strains (ctf4D).
Only the diploid tho2D and bem1D strains showed non-mating
similar to that observed with the WT BY4743 diploid strain
(Fig. 2B). Since mass mating in patches does not allow
determination of the number of cells that have converted into
cells capable of mating, we streaked out the diploid deletion strains
to obtain single colonies and tested these individual colonies for
mating ability. Using this approach we determined that only in the
case of the diploid hfiD mutant were all of the colonies completely
converted to a MATa mating type phenotype. For the diploid
ctk1D and nup133D mutants, most colonies (,93%) demonstrated
a higher rate of conversion to a MATa mating phenotype (i.e.
mated colonies were ‘‘speckled’’ with small subsets of cells within
colonies capable of growing on minimal medium as compared to
WT colonies which were ‘‘non-speckled’’) with very infrequent
conversions towards the MATa mating phenotype and only some
single colony isolates (2 and 7% respectively) were completely
converted to a MATa mating phenotype. As expected for the
diploid ctf4D mutant which demonstrates a chromosome loss
phenotype, all single isolate colonies demonstrated a high rate of
mating to either the MATa or MATa tester strains suggesting that
either copy of chromosome III can be lost due to the high rate of
malsegregation previously observed in these mutant cells.
However, few of the single colony isolates from the diploid ctf4D
strain were totally converted to either a MATao rMATa
phenotype (2 and 1% respectively) suggesting that for the majority
of cells mating type was unaffected and it is the loss of CTR4 that is
responsible for DOX sensitivity in this strain.
Deletion of diploid-specific DOX resistance genes confers
G1/S phase associated cell cycle progression defects
The identification of DOX sensitive gene deletions that are
diploid-specific suggests that these genes may mediate repair
functions prior to the completion of DNA replication. Function-
ally, these genes may impact recombinational repair of DOX-
induced lesions or alternatively, they may affect cell cycle
progression (checkpoint) in G1 or early S phase. For those
mutants that have defects affecting DNA damage checkpoint
response, they may fail to elicit checkpoint arrest and continue to
progress rapidly in the presence of damage (similar to the rad9D
strain, data not shown) to produce inviable microcolonies.
Alternatively, cells may not be able to re-enter the cell cycle
(checkpoint adaptation or recovery defect) following cell cycle
arrest and subsequent repair of DOX-induced DNA damage that
occurs in G1 or early S phase. These cells demonstrate a
prolonged arrest and fail to progress even after the repair of DNA
damage (similar to ccr4D cells). We therefore examined the cell
cycle progression of unbudded (G1) cells exposed to DOX for the
six deletion strains that have diploid-specific sensitivity to DOX
(Fig. 3). Following exposure to DOX for 15 or 30 hours, all of the
diploid deletion strains examined (bem1D, ctf4D, ctk1D, hfi1D,
nup133D,and,tho2D) demonstrated severe cell cycle progression
Figure 2. Identification of diploid-specific doxorubicin resistance genes. (A) Haploid (1n MATa) yeast deletion strains (rows 3, 4, 7, 8, 11, 12,
15, 16) were compared to their isogenic diploid (2n) deletion counterparts (rows 1, 2, 5, 6, 9, 10, 13, 14) for enhanced hypersensitivity to doxorubicin
(DOX), hydroxyurea (HU) and methyl methanesulfonate (MMS) relative to wild type (WT; rows 1, 3, 5, 7, 9, 11, 13, 15) at the indicated concentrations in
YPD agar medium. Cells were grown, diluted and plated as described in Fig. 1A. Arrows indicate direction of decreasing cell concentration. Deletion
of BEM1(rows 6, 8), CTK1 (rows 10, 12) or THO2 (rows 14, 16) show enhanced sensitivity to the lethal effects of doxorubicin as a diploid. Deletion of
AKR1 demonstrated hypersensitivity to doxorubicin in both the diploid (row 2) and haploid (row 4) derivatives. All deletion strains with the exception
of the haploid ctk1D (above) and hfiD (not shown) strains demonstrated hypersensitivity to HU and MMS when compared to WT. (B) Diploid specific
hypersensitivity of ctk1D and hfi1D strains to doxorubicin-induced cytotoxicity in the diploid BY4743 background as compared to the isogenic
BY4741 (MATa), BY4742 (MATa) haploid backgrounds. Dilution plating conditions were similar to that as described in Fig. 1A. (C) Some diploid-
specific deletion strains demonstrate enhanced mating capability as diploids. All diploid-specific gene deletions were examined for the ability to mate
to the haploid mating type tester strains147 (MATa) or 148 (MATa). WT diploid strains are non-maters. Some (ctk1D, hfi1D, nup133D and ctf4D) but not
all (tho2D, bem1D, mft1D, thp1D and thp2D) diploid strains showed enhanced capability for mating and subsequent growth on minimal (MIN) agar
medium. Representative diploid deletion strains which show enhanced mating capability (ctk1D) or no enhanced mating capability (tho2D)b y
growth on MIN medium (arrow *) are depicted.
doi:10.1371/journal.pone.0005830.g002
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described above (Fig. 1B) following exposure of WT diploid cells to
DOX in G1, 60% (12/20) of the cells produced viable
microcolonies that continued to grow into macrocolonies
(Fig. 3A). However, for each of the deletion strains that were
hypersensitive to DOX as diploids, cell cycle progression during
G1 or following G1/S transition was severely inhibited following
exposure to DOX (Fig. 3A). Mutant cells exposed to DOX in G1
demonstrated either prolonged arrest in G1 (ctf4D), arrested
predominantly as budded cells following G1/S transition (bem1D,
ctk1D, hfi1D and tho2D) or progressed to form a mixture of budded
cells and small inviable microcolonies (nup133D). All of the
mutants that progressed from G1 into S phase and arrested as
budded cells or produced microcolonies exhibited cellular lysis.
For some mutants (nup133D, ctk1D and hfi1D), this was evident at
15–30 hours following exposure to DOX (Fig. 3) while for the
others (bem1D, nup133D and tho2D) lysis occurred at 48–96 hours
following exposure (data not shown). Cell lysis following G1 to S
phase transition and arrest as large budded cells was similar to that
observed for ccr4D or pop2D mutants exposed to DOX or HU
(Fig. 1B and [39]). Furthermore, following exposure to DOX, the
majority of diploid bem1D mutant cells arrested as budded cells and
most cells exhibited cellular enlargement (swelling). Similarly, an
increase in cell size was observed for a smaller fraction of the ctk1D
mutant cells exposed to DOX (Fig. 3A). The G1/S phase
transition defects associated with these mutants and sensitivity to
the S phase specific agents HU and MMS (Fig. 2) suggest that
similar to cells with defects in the CCR4 damage response
pathway, these mutants are unable to tolerate DOX-induced
damage that induces replication stress. This apparently persists to
elicit a prolonged S phase arrest and subsequent cell lysis.
Strikingly, the diploid ctf4D mutant exhibited a prolonged G1
arrest following exposure (Fig. 3A). These mutant cells failed to
progress beyond the G1 phase of the cell cycle after extended time
periods (96 hours exposure to DOX) even though most single
unbudded cells (70%) were viable when these cells were arrayed
onto YPD medium without DOX (data not shown). Although
diploid ctf4D mutants appear to be competent for spontaneous
recombinational repair [40], (Fig. 3A) damage-induced recombi-
nation may be compromised [54] suggesting that diploid ctf4D
mutants may have persistent DOX-induced DNA damage that
elicits a prolonged G1 arrest signal that prevents cell cycle
progression similar to that seen for rad51D cells at high DOX doses
(Fig. 1C). These results suggest that mutants which demonstrate
diploid specific sensitivity to DOX have defects in recombination
and/or checkpoint functions which severely inhibit cell cycle
progression in G1 or during G1/S transition.
To confirm that the severe cell cycle defects and diploid-specific
hypersensitivity to DOX was due to the observed diploid
mutations, we complemented the bem1D, ctk1D, nup133D and
hfi1D diploid deletion mutations with plasmids expressing the
corresponding wild type gene (Fig. 3B,C). When the wild type
BEM1 gene was expressed in the diploid bem1D mutant strain, cell
cycle arrest induced by DOX was abrogated, and many cells
(50%) progressed rapidly through the cell cycle to form viable
microcolonies (Fig. 3B). The DOX-induced cell cycle response of
these cells was virtually identical to that observed with the WT
Table 2. Enhanced sensitivity of isogenic diploid and haploid
deletion strains to doxorubicin, hydroxyurea (HU) or methyl
methanesulfonate (MMS) when compared to repair
competent (WT) parental strain.
Yeast
deletion
1 DOX
2 HU
3 MMS
4
2n 1n 2n 1n 2n 1n
adk1D* .SSS .SSS .SSS .SSS S SS
akr1D .SSS .SSS .SSS .SSS .SSS SSS
arp5D SS .SSS SS S .SSS .SSS
bem1D* .SSS S .SSS SSS SS SS
ccr4D .SSS .SSS .SSS .SSS .SSS SSS
ctf4D SSS - SS - .SSS -
ctk1D SSS - S - .SSS -
dbf2D SSS SSS .SSS .SSS .SSS .SSS
dhh1D SSS SSS .SSS .SSS .SSS .SSS
hfi1D* .SSS - .SSS - SS -
hpr1D SSS .SSS SSS SSS .SSS .SSS
lge1D SSS SSS S S S SSS
lsm7D SSS SSS .SSS .SSS SSS SSS
mdm20D SS SSS S S SSS SSS
mms4D SSS SSS - - .SSS .SSS
mms22D .SSS .SSS SSS SSS .SSS .SSS
nup133D .SSS S S S SSS SSS
och1D .SSS .S S S SSSS
pat1D SS SS S S SSS SSS
plc1D .SSS .SSS .SSS .SSS S S
pop2D .SSS .SSS SSS .SSS SS SSS
rad54D .SSS .SSS .SSS .SSS .SSS .SSS
rad59D .SSS .SSS S S .SSS .SSS
rpb9D .SSS SS .SSS .SSS SS .SSS
rtt109D* .SSS .SSS SS SSS SSS SSS
slx8D .SSS .SSS SSS SSS SS -
tho2D .SSS S .SSS .SSS .SSS .SSS
tup1D .SSS .SSS - - SSS .SSS
vma7D .SSS .SSS SS SS .SSS .SSS
yaf9D SS SS - - SSS SSS
n=30 27 24 26
Other THO-associated genes
mft1D SS - S S S S
thp1D .SSS SS SSS SSS .SSS .SSS
thp2D SSS S S S SS -
*These deletion strains were detected in the haploid DOX screen [38].
1Yeast deletions identified in the diploid deletion DOX screen were cross
sensitive to ionizing radiation (see [40,39]) and Table 1. Bold indicates deletion
strains that showed diploid-specific enhanced sensitivity to DOX.
2Relative sensitivity of the diploid (2n) versus haploid (1n) deletion strains to
DOX was determined at a concentration of 50 ug/ml. Cells were grown in
liquid YPD for two days and serial 5 fold dilutions made in sterile water. Two ul
aliquots were then spotted to YPD and the DOX plates and allowed to grow
for 3 days. .SSS denotes an enhanced sensitivity for a given deletion mutant
that was greater than 125 fold over that observed for the isogenic WT of the
same ploidy; SSS denotes a 125 fold enhanced sensitivity of the mutant when
compared to WT; SS denotes a 25 fold enhanced sensitivity of the mutant
when compared to WT; S denotes a five fold enhanced sensitivity of the
mutant when compared to WT; ‘‘ - ‘‘ denotes no enhanced sensitivity of the
mutant when compared to WT.
3Relative sensitivity to hydroxyurea (HU) was determined at 200 uM.
4Relative sensitivity to methyl methanesulfonate (MMS) was determined at
2 uM.
doi:10.1371/journal.pone.0005830.t002
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for the severe cell cycle arrest phenomenon. The isogenic bem1D
cells containing an empty plasmid arrested predominantly in G1
following exposure to DOX and most (75%) failed to progress into
S phase. These cells subsequently lysed following prolonged
exposure to DOX. Interestingly, unlike the bem1D cells exposed to
DOX on synthetic complete (SC) medium the majority of single
unbudded bem1D cells (75%) exposed to DOX in rich medium
(YPD) rapidly progressed into S phase and arrested as large
budded cells. These results suggest that in SC medium the cell
cycle arrest response of bem1D cells to DOX is more rapid than
that observed in YPD resulting in a clear G1 arrest. Moreover, the
BEM1 expression plasmid suppressed the enlarged cell size
phenotype associated with the diploid bem1D strain (Fig 3B).
Using a dilution plating assay, the DOX hypersensitivity of the
diploid hfi1D, nup133D and ctk1D mutations was clearly suppressed
when the corresponding wild type gene was expressed from a
selectable plasmid (Fig. 3C). These results indicate that the
identified gene deletions (and not an acquired second site
mutation) are responsible for the diploid-specific hypersensitivity
to DOX.
The diploid-specific doxorubicin resistance genes CTK1,
HFI1 and THO2 are required for recombination
Similar to the effects of deleting members of the RAD52
recombinational repair genes, defects in recombination pathways
may result in hypersensitivity to DOX. Furthermore, we have
detected mating-type expression defects among mutants that show
diploid-specific hypersensitivity to DOX suggesting these mutants
may be decreased in their ability to undergo recombinational
repair. We therefore examined the diploid-specific DOX sensitive
mutants for spontaneous PCR-mediated gene conversion of the
endogenous his3D1 allele, a process which is defective in RAD52
group mutants [40]. As previously reported, for the IR sensitive
diploid bem1D, nup133D and ctf4D mutants, PCR-mediated gene
conversion was similar to that in WT suggesting these mutants are
recombination repair proficient [40]. Upon reexamination of these
deletion mutants gene conversion frequencies comparable to that
in WT were again observed (1.1, 4.3 and 2.4 fold increases as
compared to WT was observed for bem1D, nup133D and ctf4D
mutants respectively). However, both the diploid ctk1D and the
hfi1D mutants showed significantly enhanced levels of gene
conversion (15 and 47 fold increases as compared to WT
respectively; Fig. 3A). The enhanced levels of gene conversion
observed for the diploid ctk1D and the hfi1D mutants were
significantly greater than that observed for the WT and was similar
to that observed for the hyper-recombination mutant hpr1D (i.e. a
24 fold increase as compared to WT [40]). Furthermore, similar to
that observed in strains deleted for members of the RAD52
recombinational repair group of genes, gene conversion in the
diploid tho2D mutant was decreased 10 fold when compared to
WT (0.11 of that observed for WT, Fig. 3A). These results suggest
that for these diploid deletion mutants, recombinational repair of
DSB damage may be impaired resulting in the observed
hypersensitivity to the lethal effects of DOX. Hpr1 and Tho2
are both components of the THO complex that couples
transcription elongation to recombinational repair and defects in
these genes exhibit hyper-recombination phenotypes in haploids.
We therefore examined diploid-specific DOX sensitive deletion
strains that were defective in other members of the THO complex
(mft1D and thp2D, as well as the DOX sensitive mutant thp1D,
Table2) to determine if gene conversion was significantly altered.
We found that gene conversion in the THO associated mutant
strains was also significantly reduced when compared to WT (0.15,
0.12 and 0.12 for mft1D, thp2D and thp1D respectively). Thus,
similar to the response of RAD52 group mutants to DSB damage,
defects in the recombinational repair of DOX-induced DNA
damage could lead to persistent unrepaired DNA damage which
elicits a prolonged damage-induced checkpoint activating signal to
mediate the lethal cell cycle arrest in G1 and/or following G1/S
transition (Fig. 3).
Loss of CTK1 function has been associated with contraction of
the directly repeated rDNA sequences. Furthermore, since CTK1
has been linked genetically to multiple IR and DOX resistance
genes implicated in recombination repair (i.e., RAD50, XRS2,
MRE11, RAD51, RAD52, RAD54 and RAD55; [55]), as well as the
THO complex component MFT1 [56], we further examined the
ability of haploid ctk1D mutants to tolerate integration of plasmid
p306A2 at the ADE2 locus which results in directly repeated ade2
and a red colony phenotype. Direct integration in WT haploid
strains (BY4741) and selection for the URA3 marker results in yeast
colonies that are red following establishment of the selectable
Figure 3. Deletion of diploid-specific doxorubicin resistance genes result in cell cycle progression orrecombination defects. (A) WT and
mutant diploid deletion strains were grown to logarithmic phase in liquid YPD. Single unbudded (G1) cells were arrayed into 564 cell grids on YPD with
and without doxorubicin (50 mg/ml). Representative photomicrographs of mutant cells arrested in G1 or at G1/S following exposure to doxorubicin have
beenshownfollowing15or30 hrgrowthat30uC.OnlyWTdiploidcellswerecapableofformingviablemicrocolonieswhenexposedtodoxorubicin.Most
unbudded cells (.70%) from the WT and mutant diploid strains demonstrated rapid cell cycle progression and microcolony formation in the absence of
DOX (data not shown). The mean gene conversion frequency of the his3D1 allele to HIS
+ was determined in WT and mutant diploid strains following
transformation of a PCR fragment capable of restoring the HIS3 allele following recombination. Conversion frequencies for the WT, bem1D, ctf4D and
nup133D strains (*) have been previously reported [40]. The HIS3 conversion frequencies for the diploid ctk1D,h f i 1 D and tho2D strains are the mean of 3–
10 replica experiments61s t a n d a r dd e v i a t i o n .(B) Expression of BEM1 within the diploid bem1D strain suppresses cell cycle arrest in G1 and restores
viability following exposure to doxorubicin. The diploid bem1D strain was transformed with either empty vector or plasmid DLB1974 expressing the WT
BEM1 gene. Unbudded cells from the diploid bem1D strain with or without plasmid were grown as described above in liquid YPD or synthetic complete
glucose containingmedium lacking uracil(SC-ura) tomaintain plasmid selection. Singleunbudded cells wereexposed todoxorubicin (50 mg/ml) in either
synthetic complete glucose containing agar medium lacking uracil (SC-ura+DOX) to maintain the plasmid or YPD+DOX (for cells not containing plasmid).
The bem1D cells exposed to DOX on YPD agar plates progress from G1 into S phase and arrest as budded cells (upper panels). Cells that harbor the BEM1
expression plasmid (bem1D+BEM1) do not arrest in G1 or G1/S but form viable microcolonies by 24 hrs that continue to grow in the presence of DOX
(middle panels). Diploid bem1D cells containing vector alone, arrest in G1 when exposed to DOX on SC-ura agar medium (bottom panels). (C) Expression
plasmids containing HFI1, NUP133 and CTK1 suppress doxorubicin-induced lethality in the corresponding diploid deletion strains. Galactose-inducible
expression constructsforHFI1 and NUP133cloned withinthe selectable (URA3) plasmidBG1805orvector aloneweretransformedintohfi1D and nup133D
diploid strains respectively. The selectable (HIS3) plasmid containing CTK1 and empty vector have been previously described [59]. Plasmid bearing cells
were grown overnight at 30uC in either liquid SC-uracil containing galactose (for hfi1D and nup133D plasmid bearing strains) or SC-histidine glucose
containing medium (for the ctk1D plasmid bearing strains) in 96 well dishes. Following serial 5-fold dilution, aliquots of each cell dilution were plated to
the corresponding solid dropout medium with and without doxorubicin at the indicated concentration. Plates were photographed following 3 days
growth at 30uC. In all cases, the expression plasmid restored resistance to DOX-induced lethality in the appropriate deletion strain. Arrows indicate
direction of decreasing cell concentration.
doi:10.1371/journal.pone.0005830.g003
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transformation into haploid ctk1D (or hfi1D) strains in the BY4741
(MATa) haploid background resulted in colonies that were
predominantly white suggesting that the hyper-recombination
phenotypes associated with deletion of CTK1 or HFI1 would not
tolerate the directly repeated ade2 sequences (data not shown).
Identification of an interactive genomic network defined
by diploid-specific doxorubicin resistance genes
Using previously identified genetic and physical interactions
compiled at SGD, we determined the interaction network for the 9
genes (BEM1, CTF4, CTK1, HFI1, MFT1, NUP133, THO2, THP1
and THP2) which demonstrated diploid-specific sensitivity to
DOX. We retrieved genetic and physical interaction data sets in
Cytoscape v2.6.1 format. This query produced an initial genetic
interaction network map with 502 nodes (genes) and 1075 edges
(interactions) and a physical interaction map containing 188 nodes
with 314 edges (data not shown). We subsequently combined the
genetic and physical interaction maps and manually subtracted
essential genes that were not found in the diploid deletion
collection. Upon this map, we superimposed the DOX resistance
genes identified in this study.
The resulting union of the genetic and physical interaction maps
produced a combined map that was defined by 500 nodes with
1157 interconnected direct interactions (Fig. 4A). Within this
combined diploid-specific G1 repair network, nine highly
interactive gene nodes acted as ‘‘hubs’’ to directly interconnect
as first neighbors with seven of the other ‘‘hub’’ genes important
for the diploid-specific toleration of DOX damage. Thus, of the
nine diploid-specific DOX resistance genes, MFT1 was the most
interactive major hub member connecting to four other major
hubs (NUP133, CTK1, THO2 and THP2). When considering first
neighbor interactions, the most highly interactive of the major
hubs were the diploid-specific DOX resistance genes CTF4, HFI1,
THP1, NUP133, CTK1 and THP2 which, interacted directly with
227, 121, 112, 104, 86 and 85 other gene nodes as first neighbors
respectively (Fig. 4A). Within this combined genetic and physical
interaction network we identified a total of 123 (32.7%) of the 376
DOX resistance genes found in this study suggesting that a
diploid-specific DOX resistance gene network may be a significant
fraction of the total genes identified which mediate resistance to
DOX. Significantly, most members of the RAD52 recombina-
tional repair group that are DOX resistance genes including
RAD50, RAD51, RAD52, RAD54, RAD55, RAD57, RAD59 and
XRS2) were all found to interact jointly as a cluster with CTK1,
NUP133 and CTF4. Within this interactive cluster are other
diploid DOX resistance genes that have been implicated in DSB
repair including DCC1, ELG1 and ASF1.
Within the combined genetic/proteomic interaction map are
377 gene nodes that interconnect with the major diploid-specific
DOX resistance gene node hubs yet were not detected in the
DOX screen. Since many of these genes display genetic
interconnectivity with multiple major DOX resistance gene nodes
in a pattern similar to that for other DOX resistance genes
identified in the screen, we examined 14 of these genetically
predicted and multiply interconnected diploid deletion strains for
sensitivity to DOX, HU and/or MMS. Of the 14 mutants
examined that interconnect to multiple major DOX resistant gene
nodes (bim1D, 6 nodes; bre1D, 4 nodes; ccs1D, 2 nodes; csm1D,4
nodes; csm3D, 2 nodes; get2D, 3 nodes; hir1D, 4 nodes; lrs4D,2
nodes; mrc1D, 3 nodes; pap2D, 2 nodes; rpn4D, 4 nodes; slk19D,3
nodes; swd1D, 4 nodes and tof1D, 3 nodes) five mutants (ccs1D,
get2D, hir1D, lrs4D and pap2D) were found to express enhanced
DOX sensitivity to varying degrees (5–125 fold) when compared to
WT (Fig. 4B). When compared to WT, some mutants showed
enhanced sensitivity to HU and/or MMS without accompanying
sensitivity to DOX (bim1D, csm1D, csm3D and tof1D) and some
(bre1D, mrc1D, rpn4D, slk19D and swd1D) showed no sensitivity to
any of the DNA damaging agents tested (Fig. 4B). Thus the genetic
interaction network map was capable of identifying additional
mutations that impact on resistance to DNA damaging agents
including DOX.
In a similar manner we utilized the proteomic interaction map
within Fig. 4A to identify potential DOX sensitive diploid deletion
mutants not detected in the initial screen. We examined 14 diploid
mutants not detected in the initial DOX screen that interconnect
to DOX resistance gene nodes defined within the proteomic
network (Fig 4A). Of the 14 diploid deletion mutants examined
which interconnect to DOX resistance gene nodes (cpr7D, 2 nodes;
gbp2D, 3 nodes; hrb1D, 4 nodes; imd3D, 2 nodes; pcl9D, 2 nodes;
tex1D, 3 nodes; yck1D, 2 nodes; hog1D, 2 nodes; hta1D, 1 node;
hta2D, 2 nodes; ola1D, 2 nodes; sho1D, 1 node; swi5D, 1 node and
tos3D, 2 nodes), none were found to be DOX sensitive when
compared to WT (Fig. 4C). However, five diploid mutants (hrb1D,
imd3D, pcl9D, tex1D and yck1D) were found to exhibit enhanced
sensitivity to MMS (5 to .625 fold) when compared to WT and
one mutant (hog1D) displayed enhanced (5 fold) sensitivity to HU
(Fig. 4B). These results indicate that the interactive proteomic
network defined by previously identified diploid-specific DOX
sensitive mutants is less predictive than genetic interconnectivity in
identifying additional DOX resistance genes. Thus, construction
of interactive gene networks similar to those described here
(Fig. 4A) is a valuable tool for gene discovery and suggests that
further damage response genes not detected during primary
screening remain to be identified and characterized from within
this interaction map.
Discussion
Large sets of novel genes that mediate resistance to a variety of
DNA damaging agents have been identified using the isogenic
yeast deletion strain collections (reviewed in [57]). Surprisingly,
screens previously considered near saturation by classical muta-
genesis screening methods, including those for ionizing radiation
(IR) sensitivity [58], have uncovered a large number of previously
uncharacterized radiation resistance genes [40,39]. The fact that
some of these were the first genome-wide radiation screens
performed in diploid cells accounts in part for the discovery of
such a formidable list of new radiation resistance genes since these
screens take advantage of a novel aspect of yeast repair biology.
Yeast have a compact, non-redundant genome with few repeated
genes or repetitive DNA sequences. This promotes IR-induced
DSB damage to be preferentially repaired by homologous
recombination which requires an undamaged homolog or sister
chromatid to template a successful repair event. Haploid yeast cells
lack a homolog in G1 or early S phase, where sister chromatids
may only be partially replicated. Therefore, in unsynchronized
haploid cells that have been irradiated throughout the cell cycle, as
radiation dose increases, a rapid dose-dependent decline in
survival is observed followed by a more gradual radioresistant
decline in survival. This two-component survival response has
been attributed to the exquisite radiosensitivity of haploid cells in
G1 where no homolog is available to template a successful
recombinational repair event. Under these circumstances in G1
cells, one DSB ‘‘hit’’ is lethal. The second, radio-resistant repair
component is thought to reflect the capability of cells in late S and
G2 phases to repair IR-induced DSBs by recombination. Since
diploid mutants have a chromosome homolog in G1, they are
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PLoS ONE | www.plosone.org 13 June 2009 | Volume 4 | Issue 6 | e5830Figure 4. Genetic and proteomic interaction network of doxorubicin resistance genes identifies additional DNA damage resistance
genes. (A) Using the 9 diploid-specific DOX resistance genes identified in this study (BEM1, CTF4, CTK1, HFI1, NUP133, MFT1, THO2, THP1 and THP2;
red octagon symbols), genetic and proteomic interactions were batch downloaded from data annotated at SGD as of Nov. 2, 2008. Genetic and
physical interaction data sets were retrieved and visualized using Cytoscape v2.6.1. This initial genetic interaction network map contained a totalo f
502 nodes (genes) and 1075 edges (interactions) and the physical interaction map contained 188 nodes with 314 edges (data not shown). These were
combined and all essential genes (i.e. deletions not represented in the diploid deletion collection) were eliminated resulting in a final combined
interaction map with 500 nodes and 1154 edges. Genetic and proteomic interactions are indicated with a solid or dashed line respectively. Nodes
(genes) that were identified in the initial diploid screen as conferring DOX resistance are denoted as red circles. Using the interactive genetic map as a
predictive tool, additional DOX-resistance genes (red squares) were subsequently identified (see panel B). Some interactive genes/proteins (green
circles) did not confer resistance to DOX but did confer resistance to other DNA damaging agents (HU and/or MMS, see panels B and C). Other gene
deletion strains examined (black circles) did not show sensitivity to any of the damage agent tested when compared to WT. The diploid gene
deletions associated with the remaining nodes (orange circles) were not tested for enhanced sensitivity to DNA damaging agents. (B) Identification
of additional damage resistance genes based on genetic interactions with diploid-specific DOX resistance genes. Fourteen diploid deletion strains
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detection of previously unknown DSB repair gene mutants that
impact checkpoint and/or recombinational repair functions in G1
or early S phase prior to the completion of DNA synthesis.
Our diploid screen identified 376 gene deletions sensitive to the
DNA damaging agent doxorubicin (DOX), many of which overlap
with those that function in recombinational repair and were also
identified in our previous diploid IR screens (Table 1). However,
when a similar screen was performed in the isogenic haploid
deletion collection, far fewer haploid mutants (71) were detected
that mediated resistance to DOX [38]. We can attribute our
enhanced success at identifying DOX resistance genes to two
factors. First, our diploid screen employed DOX doses that were
greater than that used in the haploid screen. Secondly, DSB
damage such as that induced by DOX or IR is repaired
preferentially by recombinational repair mechanisms utilizing a
homologous chromosome or sister chromatid. DNA damage
resistance genes that confer resistance to DOX and function
exclusively in G1 or at the G1/S boundary prior to DNA synthesis
are undetectable as mutants in haploid cells which have no
homolog capable of serving as a template for recombination repair
prior to DNA replication. The fact that many of these DOX
resistant genes also overlap with mutants within a BRCA1
suppressor pathway that regulates transcription elongation, RNA
polymerase II stability as well as mRNA export and decay in G1
[59], mutants that affect cell size control in G1 [43,44], mutants
sensitive to oxidative damaging agents that cause damage in G1
[60,45] or mutants hypersensitive to the G1-specific toxin zymocin
(Table 1) adds further support to the identity of G1-specific repair
processes in which RNA metabolism may play a critical role in
resistance to DSB damage.
Nine diploid specific DOX resistance genes were identified and
appear to be functionally interrelated as numerous genetic and
proteomic interactions have been documented for these genes
(Fig. 4A). Functions for these genes are diverse however, all have
previously described, repair-related phenotypes. For example,
defects in CTK1, CTF4, NUP133 and members of the THO
complex all have been previously implicated in mediating repair
responses to DNA damage [61–63,54]. Furthermore, deletion of
BEM1, CTF4, HFI1 and NUP133 were previously identified as IR
resistance genes (Supplementary Table S1 [40];) and the hfi1D was
detected in the haploid DOX screen [38] although in our hands,
the sensitivity to DOX in the MATa haploid (BY4741 strain
background) was minimal at best and the isogenic MATa hfi1D
derivative displayed no sensitivity to DOX (Fig. 2B).
Detailed examination of the cell cycle progression of single,
unbudded G1 cells for six of these mutants clearly demonstrated
that all have cell cycle progression defects associated with G1 or
G1/S phase transition. However, since defects in recombination
repair could promote the persistence of DSB damage and cause
extended cell cycle delays, we examined these six mutants for the
ability to undergo PCR mediated gene conversion of the his3D1
allele by homologous recombination. As previously reported [40],
for three diploid mutants that were also IR sensitive, (bem1D, ctf4D
and nup133D), no defect in spontaneous recombination could be
identified when compared to WT suggesting that, with the
exception of the ctf4D strain that appears to be specifically deficient
for damage-induced recombination [54], the bem1D and nup133D
mutants can be provisionally classed as checkpoint defective. For
two mutants, (ctk1D and hfi1D) spontaneous recombination at
his3D1 was significantly elevated when compared to WT, while for
the diploid tho2D, gene conversion was significantly decreased.
Moreover, other THO-associated mutants that displayed en-
hanced sensitivity to DOX as diploids also demonstrated
significantly decreased levels of recombination as assayed by gene
conversion. Since this decrease in gene conversion was similar to
that observed for RAD52 group mutants [40], this suggests that
the hypersensitivity of these THO-associated diploid mutants to
DOX may arise from defects in recombinational repair of DOX-
induced DSBs. This hypo-recombination defect in gene conver-
sion for some (tho2D, mft1D, thp2D) but not all (hpr1D; [40])
mutated members of the THO complex, is in contrast to the
hyper-rec phenotypes described for THO defects when assayed by
loss of stability in directly repeated sequences integrated at LEU2
[49]. This discrepancy may reflect differences in the genetic
requirement for recombination between directly repeated inte-
grated DNA sequences which involves single-strand annealing
versus that for gene conversion [64,65] as assayed in this study by
PCR-mediated restoration of HIS3 following transformation.
The magnitude of the hyper-recombination phenotype for the
ctk1D and hfi1D mutants was similar to that described for the
diploid hpr1D mutant [40] which has been extensively character-
ized as expressing a hyper-rec phenotype for mitotic recombina-
tion events [66,67] and functions in transcription elongation [68]
further linking transcription to recombination. Therefore, it is
reasonable to suggest a model in which Ctk1, as part of the
CTDK-I kinase complex that phosphorylates the RNA polymer-
ase II C-terminal domain and facilitates transcription elongation
[69,70], also participates in recombination. Ctk1 is also required
for BRCA1-induced lethality in yeast through its participation in
an mRNA export/decay pathway [59]. Mutants in this pathway
which suppress BRCT-induced lethality in yeast, all exhibit
sensitivity to DNA damaging agents. These results suggest that
Ctk1 and the CTDK-I kinase complex may contribute indirectly
to, or alternatively, participate directly in transcription associated
recombination (TAR) in which Hpr1 and other members of the
THO complex as well as the Rad52 group of repair genes are
required for recombination between direct repeated sequences
[71,72]. Consistent with this idea is the finding that directly
repeated rDNA sequences undergo contraction in ctk1 mutant
strains [73] suggesting a hyper-rec phenotype associated with
directly repeated DNA sequences. Our finding that directly
repeated ade2 sequences are not stable in ctk1D (data not shown)
further implicates CTK1 as a gene required for the maintenance of
predicted to be DOX sensitive based on genetic interactions (rows 2–8 and 10–16) were obtained from the diploid deletion collection and tested for
enhanced sensitivity to DOX, HU and MMS when compared to WT. Cell growth, dilution and replica plating techniques were as described in Fig. 1A.
Some strains showed enhanced sensitivity to DOX (ccs1D, row 4; get2D, row 7; hir1D, row 8; lrs4D, row10 and pap2D, row12) when compared to WT
(rows 1 and 9). These strains demonstrate modest (5-fold; get2D and hir1D) to moderate (25–125 fold; ccs1D, lrs4D and pap2D) enhanced sensitivity to
DOX as indicated (*). Some strains showed enhanced sensitivity (5–125 fold) to HU (bim1D, row 2 and csm1D, row5) or MMS (tof1D, row 16) without
accompanying sensitivity to DOX. (C) Identification of additional damage resistance genes based on proteomic interactions with diploid-specific DOX
resistance genes/proteins. Diploid deletion strains predicted to be DOX sensitive based on proteomic interaction map were obtained from the diploid
deletion collection and tested for enhanced sensitivity to DOX, HU and MMS when compared to WT. Cell growth, dilution and replica plating
techniques were as described in Fig. 1A. None of the deletion strains were found to show enhanced sensitivity to DOX. However, some strains (hrb1D,
row 4; imd3D, row 5; pcl9D, row 6; tex1D, row7; and yck1D, row 8) showed enhanced sensitivity to MMS (5–625 fold) and hog1D (row 10) showed
enhanced sensitivity to HU (5 fold) when compared to WT (rows 1 and 9) as indicated (*).
doi:10.1371/journal.pone.0005830.g004
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CTDK-I function may promote RNAPII ‘‘stalling’’ during
transcription elongation and similar to other THO mutants that
interfere with transcription elongation, promote the formation of
recombinogenic DNA:RNA hybrids [74]. Such structures may
interfere with replication fork progression [75] suggesting a
possible mechanism for cell progression defects that extend into
S phase in these mutants when exposed to DOX. Finally, deletion
of CTK1 has been found to be synthetically lethal when combined
with deletions in genes required for TAR including those involved
in DSB recombination such as RAD50, RAD51, RAD52, RAD54
and RAD55 [55] as well as MFT1 [56], a key component of the
THO complex. Taken together, these results suggest that CTDK-I
transcription elongation functions may be critical for the formation
of TAR complexes.
Although IR induced DSBs were predominantly described as
arresting cells at G2/M, recent reports describing the genetic
checkpoint controls associated with DNA damage occurring in G1
are accumulating. Evidence for recombinational repair of DSBs
specifically in G1 is sparse due to the continued preference for
using haploid yeast in checkpoint and DNA damage related
studies. Furthermore, although it was originally thought that DSB
resection, which is required for homologous recombination, did
not occur during G1 in haploids [76], recent results suggest that
radiation-induced DSBs are efficiently processed for homologous
recombination in G1 haploids [77]. Since G1 haploids lack an
undamaged homolog to template recombination repair, and
NHEJ does not function efficiently on IR-induced DSBs, almost
all IR-induced DSB lesions that occur in G1 are lethal. Moreover,
DSB-induced checkpoint functions have been well documented in
G1 haploids (see below) and are equally unlikely to enhance
survival following DNA damage that induces DSBs in G1
haploids. Thus the sensing and processing of DSB damage by
haploids in G1 may be an atavistic repair trait useful only in the
parental diploid organism from which the haploid is derived
following meiosis.
Damage induced arrest in G1 or at G1/S transition has not
been as well characterized in S. cerevisiae since it is more transient
than the arrest seen at G2/M [78]. A few early studies identified a
G1 checkpoint in haploid yeast that was strongly activated by UV
or MMS damage [79–81]. WT cells arrested by alpha factor in G1
(i.e. CDC28 dependent cell cycle arrest at START) are delayed for
a short period of time (,20–40 minutes) in G1 prior to the onset of
budding following UV irradiation. This short delay is not observed
in isogenic rad9D cells [82]. A robust, RAD9 and RAD17
dependent G1 arrest following IR has been demonstrated in
haploid cells continually irradiated at a low, sub-lethal dose [83].
In fact, G1 delays as long as 18 hours could be seen for WT cells
given a single sub-lethal dose; this was not observed in rad9rad17
double mutants [83]. More recent studies have identified a G1
damage checkpoint that requires the activity of Dot1, histone H3,
and Rad9 [84] as well as Tel1 and H2A [85,86]. In addition, the
CDK Pho85 appears to be involved in G1 checkpoint adaptation
[87]. To initiate damage-mediated G1 checkpoint arrest, Rad9
binds to H2A and/or H3 methylated by Dot1 and the ATM and
ATR orthologs Tel1 and Mec1 activate Rad53p which phosphor-
ylates Swi6p and inhibits CLN1 and CLN2 expression to delay cell
cycle progression at G1/S [88]. Thus evidence for the genetic
control of G1 arrest phenomena in response to DNA damage
suggests that additional checkpoint associated genes such as those
identified in this study may contribute to enhanced survival of
diploids.
We have previously identified the CCR4 damage response
network and the checkpoint associated roles of CCR4 and DHH1
whose protein products have nuclear functions and play key roles
in mRNA decay at cytoplasmic P-bodies [40,89,39]. Character-
ization of the ccr4D and dhh1D mutants indicated that they were
required for G1 and S phase cell cycle progression following
radiation or replication stress. Furthermore, CCR4 was found to be
a member of the RAD9 epistasis group of IR resistant checkpoint
genes. Specifically, CCR4 and DHH1 behave as checkpoint
adaptation genes since following IR, diploid ccr4D or dhh1D cells
show prolonged arrest in G1; therefore they are required for re-
entry into the cell cycle following DNA damage. Strikingly, ccr4D
and dhh1D mutants are sensitive to IR only as diploids and not as
haploids, indicating that the radiation sensitive IR defect lies in G1
[39]. Surprisingly, DOX-induced DNA damage appears to be
equally lethal in isogenic diploid and haploid ccr4D cells and cell
cycle progression of diploid ccr4D cells exposed to DOX in G1 is
not delayed. Cells progress rapidly into S phase, arrest and
undergo lysis similar to that observed for the diploid bem1D, ctk1D,
hfi1D, nup133D and tho2D strains exposed to DOX in YPD. This
suggests that there may be differences in the spectrum of DSB
damage induced by IR and DOX. Moreover, the overlap of gene
deletions that confer both DOX and IR sensitivity is 28% (Table 1)
suggesting that a significant number of genes are specific for
DOX-induced DNA lesions. Alternatively, the influx of DOX into
ccr4D cells may be delayed or reduced due to sequestering of DOX
through interaction within the rich YPD agar plate medium. A
difference in the DOX-induced cell cycle arrest kinetics for diploid
bem1D mutants plated to YPD as compared to synthetic complete
medium suggests that cell cycle arrest is delayed until S phase in
YPD compared to a G1 arrest observed on synthetic complete
medium (Fig. 3B). Therefore, DOX-induced DSB damage may
not occur until G1/S transition or early S phase in rich medium
(YPD) and it would not be possible to elicit a checkpoint arrest
response in early G1. Since a recombinational repair defect can
also prolong cell cycle arrest, we determined that ccr4D cells were
recombination proficient based on three recombination-related
assays [39]. Both haploid and diploid ccr4D strains are sensitive to
S phase specific DNA damaging agents such as HU, indicating
that CCR4 haploid and diploid mutants share a common
checkpoint repair defect that extends into S phase. The checkpoint
repair defects found in ccr4D and dhh1D diploid cells have
subsequently been confirmed by other laboratories [90–93].
Since homozygosity at the mating-type locus in diploid yeast
can decrease the resistance to DNA damage and especially DSBs,
we investigated whether deletions of our diploid-specific DOX
resistance genes could affect mating type expression in diploids. In
some, (ctk1D, nup133D, hfi1D and ctf4D) but not all of the diploid
specific DOX sensitive mutants, the gene defects did affect mating
type expression in the diploid cells. Although both the diploid
ctk1D and nup133D strains maintained a predominantly MATa/
MATa phenotype, a much higher rate of conversion to MATa cells
was observed when compared to the WT diploid. In the diploid
hfi1D strain, all cells demonstrated complete conversion to the
MATa mating phenotype while in the ctf4D mutant, high rates of
conversion to both MATa or MATa was observed consistent with
the described role of Ctf4 in maintaining chromosome stability
and sister chromatid cohesion [94]. No elevated changes in
mating-type expression were observed for either bem1D or tho2D
diploid strains when compared to WT.
Repression of MATa and MATa combined with concomitant
expression of diploid-specific genes affects radiation resistance. IR
resistance is enhanced in diploid MATa/MATa cells compared to
isogenic MATa/MATa or MATa/MATa diploid cells [51–53].
This effect can occur in haploids (through de-repression of silent
mating type loci in SIR mutants) or in diploids and can suppress
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RAD51, RAD52 and RAD55 [95,53] or mutations in the post
replication repair pathway [96,97]. Almost complete repression of
the NHEJ pathway also occurs when diploid-specific genes are
expressed due to severe down-regulation of NEJ1 [98–100]. Thus,
in the absence of PRR, DSB damage appears to be preferentially
channeled into RAD52-dependent recombination in MATa/
MATa diploids by downregulating NHEJ. Moreover, MATa/
MATa expression in a haploid also impacts checkpoint adaptation
functions causing prolonged RAD9-dependent G2 arrest following
a site-specific DSB [41]. Our finding that some DOX sensitive
mutations (i.e., ctk1D, nup133D and ctf4D) are sensitive as diploids
but not as haploids appears not to be the result of diploid specific
expression of MATa since the majority of cells maintain the non-
mating MATa/MATa phenotype typical of repair proficient
diploid strains. Instead, these mutants appear to be damage
sensitive due to checkpoint or recombination defects conferred by
the loss of the individual gene function(s). Conversely, the hfiD
strain demonstrated complete conversion to a MATa mating
phenotype, yet the MATa diploid still displayed a hyper-rec gene
conversion phenotype. This suggests that during strain propaga-
tion, high rates of gene conversion at MAT resulted in selection for
a MATa/MATa diploid population yet still retained the capability
for elevated levels of homologous recombination once the MAT
conversion had occurred.
Using previously published genetic and proteomic interactions,
we successfully predicted and identified new IR resistance genes
based on interactions with members of the CCR4 damage
response network [39]. A similar approach using the published
genetic and proteomic interactions annotated within the SGD
identified five DOX resistance genes that were not detected in the
primary screen and exhibited an intermediate sensitivity to DOX
induced cytotoxicity (Fig. 4). Interestingly, all of the DOX
resistance genes successfully identified in this manner were
predictions based on genetic but not proteomic interactions. The
more robust genetic predictions used to identify these additional
DOX resistance genes are based primarily on synthetic lethality or
fitness interaction data [101,102,55]. The limitations of proteomic
predictions for gene discovery and enhanced value of genetic as
compared to proteomic interaction data has been previously noted
[103]. Presumably, the robust nature of the genetic interaction
data reflects the in vivo as opposed to the in vitro nature of proteomic
determinations that tend to miss interactions with loosely
associated proteins or misidentify interactions with overly
abundant proteins [104]. Another nine diploid deletion strains
predicted as being DOX sensitive showed little or no sensitivity to
DOX but were sensitive to HU and/or MMS indicating that our
diploid specific genes interact with other damage repair modules
not required for the spectrum of DNA damage lesions induced by
DOX. One DOX resistance gene identified in this manner is LRS4
(loss of rDNA silencing; [105]), exhibits synthetic lethal interactions
with deletions of CTK1 as well as CTK2 and CTK3, (other
members of the CTDK-I complex). Examination of the diploid
lrs4D strain indicates that cells have a G1/S progression defect
similar to that in the isogenic ctk1D diploid strain when exposed to
DOX (data not shown). This suggests that Lrs4 may be a
phosphorylation target of CTDK-I and this interaction may be
required to suppress recombination at directly repeated sequences
such as that found at the rDNA or ade2-URA3-ade2 loci.
Our yeast screen identified 376 DOX resistance genes and the
majority (76%) are conserved suggesting they may have clinical
relevance. DOX is a highly effective anthracycline chemothera-
peutic agent that targets solid tumors of the breast and other
cancers; however, dosage has to be carefully regulated and
monitored to avoid the potentially life threatening complications
associated with cardiotoxicity. DOX is a DNA damaging agent
that produces DNA DSBs in part through the production of
reactive oxygen species (ROS). The site of ROS production
appears to be the mitochondrion and yeast mutants that lack
functional mitochondria are indeed more resistant to DOX
(Fig. 1E). Cardiotoxicity appears to occur because DOX-induced
ROS is excessive in mitochondria rich tissues such as the heart,
resulting in respiratory failure and/or severe mitochondrial
damage. This in turn results in cardiomyocyte cell death and
subsequent cardiac failure. Of significance, is the fact that our
screen is enriched for mutations (n=30) in genes that are
associated with mitochondrial functions, and most (29/
30=96%) are highly conserved (Table S3). Presumably, these
mutations may promote enhanced DOX mediated ROS produc-
tion and/or allow greater access of DOX into the mitochondrial
compartment. Mutations or polymorphisms in these genes within
human populations may therefore predict cardiotoxicity due to
enhance hypersensitivity of cardiac tissue to DOX.
DOX resistance in tumors can occur which decreases the
efficacy of this chemotherapeutic agent. In some cases this can
severely limit the clinical usage of this otherwise effective class of
drugs. We propose that tumor hypersensitivity and/or resistance
to DOX is genetically determined and that the orthologs identified
in this study offer many new potential genes that could be targeted
for inactivation to increase tumor sensitivity to DOX chemother-
apy. Validating these human orthologs as genes which confer
resistance to DOX could allow strategies to be designed that
sensitize DOX resistant cancers that would be normally refractory
to treatment with this drug. From our extensive list of highly
conserved DOX resistance genes identified in yeast, we utilized
BLAST analysis to identify five DOX resistance targets that show
high homology to proteins previously identified to be mutated in
breast cancer (Table S4; [106]). These targets may be predictive of
an enhanced and more complete clinical response to lower doses
of the drug. Recently, one of these predicted targets, PRPF4B
(PRP-4) has been validated as a DOX resistance gene in ovarian
cancer cells [107]. Moreover, these authors also identified and
validated that a component of the human THO complex
(THOC1) is a DOX resistance gene in human ovarian cells
[107]. Of further significance is the finding that a human TREX
component (hTREX84), which is required for transcription
elongation and mRNA export is significantly overexpressed in
human breast cancers [108]. Since the conserved THO/TREX
complexes interact together in both yeast and human cells to link
transcription elongation to mRNA export [109], these results
suggest that tumors with THO/TREX expression abnormalities
may be DOX hypersensitive. As THOC1 is the ortholog of yeast
HPR1 (Table 2), expression defects associated with the other THO
complex orthologs (THO2, MFT1 and THP2) are similarly
predicted to confer DOX sensitivity in human cells. If expression
or mutational defects in these genes can be identified, they may be
important determinants for predicting an effective clinical
response to DOX therapy.
Supporting Information
Table S1 Yeast diploid deletion mutants hypersensitive to the
lethal effects of doxorubicin with associated sensitivity to the toxin
zymocin. Doxorubicin hypersensitivity in the diploid deletion
strains was scored from 1–3 (complete description in Results
section of text) with 1 being the least sensitive and 3 the most
sensitive. Sensitivity to zymocin in the diploid deletion strains was
scored 1–3 with 1 being the least sensitive and 3 being the most
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Diploid deletions that are cross sensitive to ionizing radiation (IR)
have been indicated in bold. References that describe haploid
deletion strains that are sensitive to doxorubicin, are defective in
G1 cell size control and cross sensitive to oxidative damaging
agents are described in the text (see Results section for detailed
description). Human orthologs and associated P-values were
determined by protein BLAST analysis. Yeast protein sequences
were obtained from SGD and BLAST analysis was used to identify
orthologs within the human reference protein database at NCBI.
Gene functions and cellular component of corresponding yeast
proteins were obtained from SGD.
Found at: doi:10.1371/journal.pone.0005830.s001 (0.11 MB
XLS)
Table S2 Yeast diploid deletion mutants that show reduced
(slow) growth in response to doxorubicin. Table listing diploid
yeast gene deletions that have a slow growth rate when exposed to
doxorubicin. Deletion strains were scored 1–2 with 1 being the
least inhibited and 2 being more inhibited when exposed to
doxorubicin (see text Results section for complete description).
Zymocin sensitivity of diploid deletion strains has been described
in Table S1. Cross sensitivity to IR (bold) has been indicated for
the diploid deletion strains. Cross sensitivity of haploid deletion
strains to doxorubicin, G1 size control and oxidative damage are
identical to that described in Table S1. Gene function, cellular
component location of protein products, human orthologs and
associated P-values are identical to that described in Table S1.
Found at: doi:10.1371/journal.pone.0005830.s002 (0.10 MB
XLS)
Table S3 Highly conserved mitochondrial gene targets that
mediate doxorubicin resistance in diploid yeast. Table listing
doxorubicin sensitive yeast diploid gene deletions with products
implicated in mitochondrial function (see text Discussion section
for complete description).
Found at: doi:10.1371/journal.pone.0005830.s003 (0.06 MB
DOC)
Table S4 Yeast doxorubicin resistance genes whose protein
products are orthologs of human proteins encoded by genes
mutated in breast cancer. Table listing yeast doxorubicin
resistance proteins that are orthologs of human proteins encoded
by genes found to be mutated in breast cancer (see text Discussion
section for complete description).
Found at: doi:10.1371/journal.pone.0005830.s004 (0.08 MB
DOC)
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